Steven K. Grinspoon

Steven K. Grinspoon

Auto-generated profile, based on publicly available information

Steven K. Grinspoon

Cardiometabolic Endocrinology Section, Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2007 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
VTVirginia A. Triant
Virginia A. Triant
HLHang Lee
Hang Lee
CHColleen Hadigan
Colleen Hadigan
SGSteven K. Grinspoon
Steven K. Grinspoon
Context: Metabolic changes and smoking are common among HIV patients and may confer increased cardiovascular risk. Objective: The aim of the study was to determine acute myocardial infarction (AMI) rates and cardiovascular risk factors in HIV compared with non-HIV patients in two tertiary care hospitals. Design, Setting, and Participants: We conducted a health care system-based cohort study using a large data registry with 3,851 HIV and 1,044,589 non-HIV patients. AMI rates were determined among patients receiving longitudinal care between October 1, 1996, and June 30, 2004. Main Outcome Measures: The primary outcome was myocardial infarction, identified by International Classification of Diseases coding criteria. Results: AMI was identified in 189 HIV and 26,142 non-HIV patients. AMI rates per 1000 person-years were increased in HIV vs. non-HIV patients [11.13 (95% confidence interval [CI] 9.58–12.68) vs. 6.98 (95% CI 6.89–7.06)]. The HIV cohort had significantly higher proportions of hypertension (21.2 vs. 15.9%), diabetes (11.5 vs. 6.6%), and dyslipidemia (23.3 vs. 17.6%) than the non-HIV cohort (P < 0.0001 for each comparison). The difference in AMI rates between HIV and non-HIV patients was significant, with a relative risk (RR) of 1.75 (95% CI 1.51–2.02; P < 0.0001), adjusting for age, gender, race, hypertension, diabetes, and dyslipidemia. In gender-stratified models, the unadjusted AMI rates per 1000 person-years were higher for HIV patients among women (12.71 vs. 4.88 for HIV compared with non-HIV women), but not among men (10.48 vs. 11.44 for HIV compared with non-HIV men). The RRs (for HIV vs. non-HIV) were 2.98 (95% CI 2.33–3.75; P < 0.0001) for women and 1.40 (95% CI 1.16–1.67; P = 0.0003) for men, adjusting for age, gender, race, hypertension, diabetes, and dyslipidemia. A limitation of this database is that it contains incomplete data on smoking. Smoking could not be included in the overall regression model, and some of the increased risk may be accounted for by differences in smoking rates. Conclusions: AMI rates and cardiovascular risk factors were increased in HIV compared with non-HIV patients, particularly among women. Cardiac risk modification strategies are important for the long-term care of HIV patients.

6 January 2005 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SGSteven Grinspoon
Steven Grinspoon
ACAndrew Carr
Andrew Carr
Metabolic complications, including dyslipidemia, insulin resistance, and altered fat distribution (loss of subcutaneous fat and a relative increase in central fat), are common in adults infected with the human immunodeficiency virus (HIV) who are receiving highly active antiretroviral therapy (HAART). These complications may increase these patients' risk of cardiovascular disease. In this review, we discuss progress in the understanding of pathogenetic mechanisms of cardiovascular risk in this population and the development of treatment strategies.

1 January 2001 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
CHColleen Hadigan
Colleen Hadigan
JMJames B. Meigs
James B. Meigs
CCColleen Corcoran
Colleen Corcoran
PRPetra Rietschel
Petra Rietschel
SPSarah Piecuch
Sarah Piecuch
SGSteven Grinspoon
Steven Grinspoon
We evaluated metabolic and clinical features of 71 HIV-infected patients with lipodystrophy by comparing them with 213 healthy control subjects, matc

25 July 2012 in JAMA
Verified
Journal Article
Open access
PDF file
SSSharath Subramanian
Sharath Subramanian
ATAhmed Tawakol
Ahmed Tawakol
TBTricia H. Burdo
Tricia H. Burdo
SASuhny Abbara
Suhny Abbara
JWJeffrey Wei
Jeffrey Wei
SGSteven K. Grinspoon
Steven K. Grinspoon
Coronary artery disease (CAD) is significantly increased in patients infected with human immunodeficiency virus (HIV), but the specific mechanisms remain unknown.1 Immunological modulations may play an important role in the pathogenesis of atherosclerosis in patients with HIV. Patients with HIV demonstrate a high prevalence of noncalcified coronary atherosclerotic lesions that are increased in association with markers of macrophage activation.2 This is significant because infiltration of activated monocytes and macrophages into the endothelium contributes to the development of vulnerable atherosclerotic plaque susceptible to rupture.3,4

1 September 2008 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
VTVirginia A. Triant
Virginia A. Triant
TBTodd T. Brown
Todd T. Brown
HLHang Lee
Hang Lee
SGSteven K. Grinspoon
Steven K. Grinspoon
Context: Reduced bone mineral density has been demonstrated among HIV-infected patients, but fracture prevalence is unknown. Objective: The objective of the study was to compare fracture prevalence in HIV-infected and non-HIV-infected patients. Design: This was a population-based study. Setting: The study was conducted at a large U.S. health care system. Patients: A total of 8525 HIV-infected and 2,208,792 non-HIV-infected patients with at least one inpatient or outpatient encounter between October 1, 1996, and March 21, 2008, was compared. Main Outcome Measure: Fracture prevalence using specific International Classification of Diseases, Ninth Revision, Clinical Modification fracture codes was measured. Results: The overall fracture prevalence was 2.87 vs. 1.77 patients with fractures per 100 persons in HIV-infected, compared with non-HIV-infected patients (P < 0.0001). Among females, the overall fracture prevalence was 2.49 vs. 1.72 per 100 persons in HIV-infected vs. non-HIV-infected patients (P = 0.002). HIV-infected females had a higher prevalence of vertebral (0.81 vs. 0.45; P = 0.01) and wrist (1.31 vs. 0.83; P = 0.01) fractures per 100 persons, compared with non-HIV-infected females but had a similar prevalence of hip fractures (0.47 vs. 0.56; P = 0.53). Among males, the fracture prevalence per 100 persons was higher in HIV-infected vs. non-HIV-infected patients for any fracture (3.08 vs. 1.83; P < 0.0001), vertebral fractures (1.03 vs. 0.49; P < 0.0001), hip fractures (0.79 vs. 0.45; P = 0.001), and wrist fractures (1.46 vs. 0.99; P = 0.001). Fracture prevalence was higher relative to non-HIV-infected patients among African-American and Caucasian females and Caucasian males. Conclusions: Fracture prevalence is increased in HIV-infected compared with non-HIV-infected patients.

15 October 2011 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
TBTricia H. Burdo
Tricia H. Burdo
JLJanet Lo
Janet Lo
SASuhny Abbara
Suhny Abbara
JWJeffrey Wei
Jeffrey Wei
MDMichelle E. DeLelys
Michelle E. DeLelys
SGSteven Grinspoon
Steven Grinspoon
Background. Pro-inflammatory monocytes/macrophages may contribute to increased atherosclerosis in human immunodeficiency virus (HIV)–infected patients. We investigate—to our knowledge, for the first time—sCD163 and other markers of monocyte activation in relationship to atherosclerotic plaque in HIV-infected patients. Methods. One hundred two HIV-infected and 41 HIV-seronegative men with equivalent cardiovascular risk factors and without history of coronary artery disease were prospectively recruited and underwent computed tomography coronary angiography. Results. sCD163 levels and presence of plaque were significantly higher among antiretroviral-treated subjects with undetectable HIV RNA levels, compared with seronegative controls (1172 ± 646 vs. 883 ± 561 ng/mL [P = .02] for sCD163 and 61% vs. 39% [P = .03] for presence of plaque). After adjusting for age, race, lipids, blood pressure, glucose, smoking, sCD14, and HIV infection, sCD163 remained independently associated with noncalcified plaque (P = .008). Among HIV-infected patients, sCD163 was associated with coronary segments with noncalcified plaque (r = 0.21; P = .04), but not with calcium score. In contrast, markers of generalized inflammation, including C-reactive protein level, and D-dimer were not associated with sCD163 or plaque among HIV-infected patients. Conclusions. sCD163, a monocyte/macrophage activation marker, is increased in association with noncalcified coronary plaque in men with chronic HIV infection and low or undetectable viremia. These data suggest a potentially important role of chronic monocyte/macrophage activation in the development of noncalcified vulnerable plaque. Clinical Trial Registration. NCT00455793.